Comparison · NCT04171700-653bcc4c
Rucaparib Cohort A vs Rucaparib Cohort B: Best Overall Response Rate by Investigator
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rucaparib Cohort A vs Rucaparib Cohort B: Best Overall Response Rate by Investigator. Trial comparisons, record NCT04171700-653bcc4c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04171700-653bcc4c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.148 | 0.0796 | 0.257 | wilson | |
| Risk in group 2 | 0.1 | 0.0279 | 0.301 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0475 | -0.165 | 0.179 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.48 | 0.347 | 6.27 | log | |
| Odds ratio, group 1 over group 2 | 1.56 | 0.307 | 7.9 | log | |
| Number needed to treat, for one more participant with the outcome on Rucaparib Cohort A than on Rucaparib Cohort B | 21 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rucaparib Cohort A | Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D. | 9 | 61 | OG000 |
| Group 2 | Rucaparib Cohort B | Participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, or RAD51B. | 2 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Best Overall Response Rate by Investigator
- Description
- Best overall response rate as assessed by the investigator by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in participants with advanced prostate cancer).
- Time frame
- From first dose of study drug until disease progression (up to approximately 2 years)
- Population
- Efficacy population - all participants evaluable for response by RECIST v1.1 (or modified RECIST v1.1/PCWG3 for mCRPC participants).
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
- NCT number
- NCT04171700
- Phases
- PHASE2
- Conditions
- Solid Tumor
- Interventions
- Rucaparib
- Lead sponsor
- pharmaand GmbH
- Results first posted
- 2023-10-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04171700?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04171700-653bcc4c